Abstract: A composition comprising glucoraphanin for use in: reducing fasting serum glucose levels in a subject administered with said composition when compared to a subject not administered said composition; and/or preventing diabetes mellitus and/or a condition associated therewith, treating diabetes mellitus and/or a condition associated therewith, or a combination thereof in a subject; wherein the composition is intermittently administered to the subject between about 1 to about 5 times per week such that said subject is administered with a weekly dose of between about 300 to about 2500 ?moles of glucoraphanin, as well as uses of a composition prepared from a high glucosinolate broccoli and/or methods of: reducing fasting serum glucose levels in a subject having elevated fasting serum glucose levels; preventing diabetes mellitus and/or a condition associated therewith in a subject; treating a subject having diabetes mellitus and/or a condition associated therewith; or combinations thereof.

Abstract: The present invention relates to S-methylcysteine sulfoxide and compositions thereof for use in the treatment or prevention of prostate cancer. It also relates to analogues, derivatives or metabolites of S-methylcysteine sulfoxide for use in the treatment or prevention of prostate cancer. Compositions of S-methylcysteine sulfoxide or its analogues, derivatives or metabolites may be provided for oral consumption, for example as a pharmaceutical composition, a medicament or a food composition.

Abstract: A composition comprising glucoraphanin for use in: reducing fasting serum glucose levels in a subject administered with said composition when compared to a subject not administered said composition; and/or preventing diabetes mellitus and/or a condition associated therewith, treating diabetes mellitus and/or a condition associated therewith, or a combination thereof in a subject; wherein the composition is intermittently administered to the subject between about 1 to about 5 times per week such that said subject is administered with a weekly dose of between about 300 to about 2500 ?moles of glucoraphanin, as well as uses of a composition prepared from a high glucosinolate broccoli and/or methods of: reducing fasting serum glucose levels in a subject having elevated fasting serum glucose levels; preventing diabetes mellitus and/or a condition associated therewith in a subject; treating a subject having diabetes mellitus and/or a condition associated therewith; or combinations thereof.

Abstract: The present invention relates to a composition comprising a high glucosinolate Cruciferous vegetable (such as a high glucosinolate broccoli) having a high level of glucosinolate and/or at least one derivative thereof for use in the treatment or prevention of a cardiovascular disease or for use in promoting heart and/or cardiovascular health.

Abstract: The present invention relates to a composition comprising a high glucosinolate Cruciferous vegetable (such as a high glucosinolate broccoli) having a high level of glucosinolate and/or at least one derivative thereof for use in the treatment or prevention of a cardiovascular disease or for use in promoting heart and/or cardiovascular health.

Abstract: The present invention concerns compositions that may be used in the prevention or treatment of medical conditions characterised by having an inflammatory component. The compositions comprise a therapeutically effective amount of an isothiocyanate (ITC). The composition may comprise further anti-inflammatory agents (e.g. plant-derived polyphenols).

Abstract: The invention relates to a method for producing Brassica oleracea with elevated anticarcinogenic glucosinolate derivatives. The elevated levels are obtained by crossing wild Brassica oleracea species with Brassica oleracea breeding lines, and subsequently selecting hybrids with levels of 4 -methylsulfinylbutyl and/or 3-methylsulfinylpropyl glucosinolates elevated above that initially found in Brassica oleracea breeding lines. The invention also relates to edible Brassica plants, such as broccoli plants, with elevated levels of 4-methylaulfinylbutyl glucosinolate and/or 3 -methylsulfinylpropyl glucosinolates, and to seeds of such plants.